Advanced search
Start date
Betweenand

Intravitreal ranibizumab combined with green diode laser (ETDRS) or pattern scan laser (Pascal) Panretinal Photocoagulation (PRP) combined with intravitreal ranibizumab (IVR) versus only intravitreal ranibizumab for proliferative diabetic retinophaty

Grant number: 13/02169-2
Support type:Scholarships in Brazil - Doctorate (Direct)
Effective date (Start): November 01, 2013
Effective date (End): July 13, 2014
Field of knowledge:Health Sciences - Medicine
Principal researcher:Rodrigo Jorge
Grantee:Rafael de Montier Pompeu Barroso
Home Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

The DRS and ETDRS showed the benefits of preventing losses of vision acuity and new vessels' progress in high risk proliferative diabetic retinophaty by panretinal laser photocoagulation (PRP). However, the PRP parameters have been related to extensive damages in retina's function and morphology as perimetry's contraction, worsening macular' aedema and sometimes being painful for patients. According to this settings, new therapies as intravitreal antiVEGF (ranibizumab or bevacizumab) and pattern scan laser (Pascal) have been included in order to optimize desease's control, decreasing retinal damage and improving patient's adherence. Objectives: To evaluate the retinal effects of panretinal laser photocoagulaton with single spot (ETDRS-PRP) comparing with panretinal laser photocoagulaton with multiple spot (PASCAL-PRP) associated to intravitreal Ranibizumab (IVR), by changes in total area of new vessels activity, visual acuity, retinal electral physiology and visual perimetry. Methods: Prospective and randomized clinical trial with 45 patients with hPDR divided into 3 groups according to the treatment: ETDRS + IVR (n=15), PASCAL + IVR (n=15) and IVR (n=15). Evaluations will include measurement of best-corrected visual acuity, ISCEV-Standard full-field electroretinogram (ERG), full-field scotopic threshold, visual field (30-2-threshold), retinography and fluorescein angiography, and Optical Coherence Tomography (OCT). Exams will be performed at baseline, 4, 8 and 12 weeks after treatment. Expected results: We expect to describe the changes in retinal function and morphology associated with the different treatment strategies, and to estimate their relationships with therapeutic efficiency. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
TOSCANO, LUIZA; MESSIAS, ANDRE; MESSIAS, KATHARINA; DE CENCO LOPES, RAFAELLA; RIBEIRO, JEFFERSON A. SANTANA; SCOTT, INGRID U.; JORGE, RODRIGO. Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study. DOCUMENTA OPHTHALMOLOGICA, v. 143, n. 3 AUG 2021. Web of Science Citations: 0.
RAFAEL DE MONTIER P. BARROSO; KATHARINA MESSIAS; DENNY MARCOS GARCIA; JOSÉ AUGUSTO CARDILLO; INGRID U. SCOTT; ANDRE MESSIAS; RODRIGO JORGE. ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy. Arquivos Brasileiros de Oftalmologia, v. 83, n. 6, p. 526-534, Dez. 2020. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.